SCHEMBL3146993

SCHEMBL3146993

Fc1ccc(C#CCN2CCN(c3nccs3)CC2)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 3/20 0.37
AOC3 Q16853 2/20 0.36
PARP1 P09874 2/20 0.36
EED O75530 1/20 0.36
DRD2 P14416 3/20 0.36
HTR2A P28223 1/20 0.36
HRH1 P35367 1/20 0.36
DRD4 P21917 1/20 0.35
SCD O00767 1/20 0.35
KMT2A Q03164 1/20 0.34
SLC6A7 Q99884 1/20 0.34
OGA O60502 1/20 0.34
TNK1 Q13470 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3150916 0.86 DRD2 (0.41) NPC1RAB9AMEN1AOC3PARP1
SCHEMBL3151935 0.83 LMNA (0.44) NPC1RAB9AMEN1DRD2HTR2A
SCHEMBL3152394 0.82 GRM5 (0.40) NPC1RAB9AMEN1EEDDRD2
SCHEMBL3147334 0.80 NPC1 (0.40) NPC1RAB9AMEN1PARP1EED
SCHEMBL3151516 0.78 AOC3 (0.40) NPC1RAB9AMEN1AOC3PARP1
SCHEMBL3150069 0.78 EED (0.44) NPC1RAB9AMEN1AOC3PARP1
SCHEMBL3151720 0.78 EED (0.39) NPC1RAB9AMEN1PARP1EED
SCHEMBL3146998 0.78 SCD (0.45) BRD4NPC1RAB9AMEN1AOC3
SCHEMBL3151301 0.78 DRD2 (0.42) NPC1RAB9AMEN1AOC3DRD2
SCHEMBL3151364 0.77 DRD2 (0.43) NPC1RAB9AMEN1DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 BRD4 1344/4885NPC1 1584/4885RAB9A 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.